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2009-2010 Influenza Season 
Week 15 ending April 17, 2010 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 15 (April 11-17, 2010), influenza activity decreased in the U.S. 
o 37 (2.1%) specimens tested by U.S. World Health Organization (WHO) and National 
Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories and 
reported to CDC/Influenza Division were positive for influenza. 
o All 20 subtyped influenza A viruses were 2009 influenza A (H1N1). 
o The proportion of deaths attributed to pneumonia and influenza (P&I) was at the epidemic 
threshold.  
o No influenza-associated pediatric deaths were reported. 
o The proportion of outpatient visits for influenza-like illness (ILI) was 1.1%, which is below the 
national baseline of 2.3%.  All 10 regions reported ILI below region-specific baseline levels. 
o No states reported widespread or regional influenza activity.  Four states reported local 
influenza activity.  The District of Columbia, Guam, Puerto Rico, and 31 states reported 
sporadic influenza activity.  Fourteen states reported no influenza activity, and the U.S. 
Virgin Islands and one state did not report. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative since August 30, 2009 (Week 35)* 
HHS 
Surveillance 
Regions** 
Out-
patient 
ILI† 
% 
positive 
for flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H1) A (H3) 2009 A (H1N1) 
A  
(unable 
to sub-
type)¥ 
A 
(Subty-
ping not 
perfor-
med) 
B  Pediatric Deaths 
Nation Normal 2.1% 0 of 54 34 66 66,682 288 22,439 297 272 
Region 1 Normal  0.7% 0 of 6 4 5 3,404 14 503 12 6 
Region 2 Normal 0.4% 0 of 4 8 6 1,809 0 2,404 14 19 
Region 3 Normal 1.4% 0 of 6 3 12 10,716 48 1,453 18 14 
Region 4 Normal 7.7% 0 of 8 0 7 9,855 95 4,703 90 52 
Region 5 Normal 3.8% 0 of 6 8 25 9,503 46 1,580 19 36 
Region 6 Normal 2.9% 0 of 5 2 3 5,188 19 5,409 56 73 
Region 7 Normal 6.0% 0 of 4 3 1 3,300 3 847 9 8 
Region 8 Normal 1.7% 0 of 6 4 2 9,870 0 3,945 56 16 
Region 9 Normal 1.8% 0 of 5 0 4 8,348 49 1,247 19 38 
Region 10 Normal 1.2% 0 of 4 2 1 4,689 14 348 4 10 
*Influenza season officially begins each year at week 40. This season data from week 35 will be included to show the trend of influenza activity before the official start of the 
2009-10 influenza season. 
**HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, US Virgin Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, 
SC, TN; Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE; Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; 
and Region 10: AK, ID, OR, WA).  Use of the national baseline for regional data or regional baselines for state data is not appropriate. 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
‡ National data are for current week; regional data are for the most recent three weeks. 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and U.S. Virgin Islands. 
¥ Subtyping results for the majority of specimens in this category were inconclusive because of low virus titers. 
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U.S. Virologic Surveillance:  WHO and NREVSS collaborating laboratories, located in all 50 
states and Washington, D.C., report to CDC the number of respiratory specimens tested for 
influenza and the number positive by influenza type and subtype. The results of tests performed 
during the current week are summarized in the table below. 
 Week 15 
No. of specimens tested 1,749 
No. of positive specimens (%) 37 (2.7%) 
Positive specimens by type/subtype  
Influenza A 35 (94.6%) 
          A (2009 H1N1)  20 (57.1%)  
          A (subtyping not performed)          15 (42.9%)
          A (unable to subtype)  0 (0.0%)  
          A (H3)                0 (0.0%)  
          A (H1) 0 (0.0%)
Influenza B 2 (5.4%) 
 
During week 15, all 20 subtyped influenza A viruses reported to CDC were 2009 influenza A (H1N1) 
viruses. 
 
Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS Collaborating 
Laboratories, National Summary, August 30, 2009-April 17, 2010 
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Pneumonia and Influenza Hospitalization and Death Tracking: The Aggregate Hospitalization 
and Death Reporting Activity (AHDRA) system was implemented on August 30, 2009, and replaced 
the weekly report of laboratory confirmed 2009 H1N1-related hospitalizations and deaths that 
began in April 2009.  Jurisdictions report to CDC the number of hospitalizations and deaths 
resulting from all types or subtypes of influenza, not just those associated with 2009 H1N1.  Counts 
were reset to zero on August 30, 2009.  From August 30, 2009 – April 3, 2010, 41,883 laboratory-
confirmed influenza-associated hospitalizations and 2,125 laboratory-confirmed influenza-
associated deaths were reported to CDC.   
Reporting of influenza-associated hospitalizations and deaths through AHDRA was discontinued 
during the week ending April 3, 2010 (week 13). CDC will continue to use its traditional influenza 
surveillance systems to track the remainder of the 2009-10 season. 
Weekly Laboratory-Confirmed Influenza-Associated Hospitalizations and 
Deaths Reported to AHDRA,  
National Summary, August 30, 2009 – April 3, 2010 
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Antigenic Characterization: CDC has antigenically characterized two seasonal influenza A 
(H1N1), 13 influenza A (H3N2), 24 influenza B, and 1,723 2009 influenza A (H1N1) viruses 
collected since September 1, 2009.  
Both seasonal influenza A (H1N1) viruses tested were related to the influenza A (H1N1) 
component of the 2009-10 Northern Hemisphere influenza vaccine (A/Brisbane/59/2007).  
The 13 influenza A (H3N2) viruses tested showed reduced titers with antisera produced against 
A/Brisbane/10/2007, the 2009-2010 Northern Hemisphere influenza A (H3N2) vaccine component, 
and were antigenically related to A/Perth/16/2009, the WHO recommended influenza A (H3N2) 
component of the 2010 Southern Hemisphere and 2010-11 Northern Hemisphere vaccine 
formulations. 
Influenza B viruses currently circulating globally can be divided into two distinct lineages 
represented by the B/Yamagata/16/88 and B/Victoria/02/87 viruses.  The influenza B component 
of the 2009-10 and 2010-11 Northern Hemisphere vaccines belongs to the B/Victoria lineage, 
which currently predominates in most countries where circulation of influenza B has been 
reported.  Twenty-three (95.8%) of the 24 influenza B viruses from the U.S. tested belong to the 
B/Victoria lineage and are related to the influenza vaccine component for the 2009-10 and 2010-
11 Northern Hemisphere influenza B vaccine strain (B/Brisbane/60/2008). One (4.2%) virus tested 
belongs to the B/Yamagata lineage.   
One thousand seven hundred seventeen (99.7%) of 1,723 2009 influenza A (H1N1) viruses tested 
are related to the A/California/07/2009 (H1N1) reference virus selected by WHO as the 2009 H1N1 
vaccine virus, and as a component in the 2010-11 Northern Hemisphere vaccine.  Six viruses 
(0.3%) tested showed reduced titers with antiserum produced against A/California/07/2009.  
Annual influenza vaccination is expected to provide the best protection against those virus strains 
that are related to the vaccine strains, but limited to no protection may be expected when the 
vaccine and circulating virus strains are so different as to be from different lineages.  Antigenic 
characterization of 2009 influenza A (H1N1) viruses indicates that these viruses are only distantly 
related antigenically and genetically to seasonal influenza A (H1N1) viruses, suggesting that little to 
no protection would be expected from vaccination with seasonal influenza vaccine.   
Composition of the 2010-11 Influenza Vaccine:  WHO has recommended vaccine strains for the 
2010-11 Northern Hemisphere trivalent influenza vaccine, and FDA has made the same 
recommendations for the U.S. influenza vaccine.  Both agencies recommend that the vaccine 
contain A/California/7/2009-like (2009 H1N1), A/Perth/16/2009-like (H3N2), and 
B/Brisbane/60/2008-like (B/Victoria lineage) viruses.  A seasonal influenza A (H1N1) component is 
not included in the 2010-11 formulation, and the A (H3N2) component has been changed from the 
2009-10 Northern Hemisphere vaccine formulation.  This recommendation was based on 
surveillance data related to epidemiology and antigenic characteristics, serological responses to 
2009-10 trivalent seasonal and 2009 H1N1 monovalent vaccines, and the availability of candidate 
strains and reagents. 
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Antiviral Resistance: Since September 1, 2009, one seasonal influenza A (H1N1), 13 influenza A 
(H3N2), 23 influenza B, and 1,705 2009 influenza A (H1N1) virus isolates have been tested for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir), and 2,811 2009 influenza A 
(H1N1) original clinical samples were tested for a single known mutation in the virus that confers 
oseltamivir resistance.  In addition, one seasonal influenza A (H1N1), 13 influenza A (H3N2), and 
1,705 2009 influenza A (H1N1) virus isolates have been tested for resistance to the adamantanes 
(amantadine and rimantadine).  The results of antiviral resistance testing performed on these 
viruses are summarized in the table below. Additional laboratories perform antiviral testing and 
report their results to CDC, and positive results from that testing are included in the footnote. 
Antiviral Resistance Testing Results on Samples Collected Since September 1, 2009. 
 Viruses tested (n) 
Resistant 
Viruses, 
Number (%) 
Viruses 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Isolates 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Oseltamivir Zanamivir Adamantanes 
Seasonal 
Influenza A 
(H1N1) 
1 1 (100.0) 0 0 (0) 1 0 (0) 
Influenza A 
(H3N2) 13 0 (0) 0 0 (0) 13 13 (100.0) 
Influenza B 23 0 (0) 0 0 (0) N/A* N/A* 
2009 
Influenza A  
(H1N1) 
4,516 52†‡ (1.2) 1,705 0 (0) 1,705 1,701 (99.8) 
*The adamantanes (amantadine and rimantadine) are not effective against influenza B viruses. 
†Two screening tools were used to determine oseltamivir resistance: sequence analysis of viral genes and a neuraminidase inhibition assay. 
‡ Additional laboratories perform antiviral resistance testing and report their results to CDC.  Three additional oseltamivir resistant 2009 influenza 
A (H1N1) virus has been identified by these laboratories since September 1, 2009, bringing the total number to 55. 
 
All 20 subtyped influenza A virus reported during week 15 were 2009 influenza A (H1N1) viruses, 
and nearly all 2009 influenza A (H1N1) viruses tested since April 2009 have been resistant to the 
adamantanes (amantadine and rimantadine).   
 
Antiviral treatment with oseltamivir or zanamivir is recommended for all patients with confirmed or 
suspected influenza virus infection who are hospitalized, are at higher risk for influenza 
complications, or who have lower respiratory tract or progressive disease.  Additional information on 
antiviral recommendations for treatment and chemoprophylaxis of influenza virus infection is 
available at http://www.cdc.gov/H1N1flu/recommendations.htm.   
 
2009 influenza A (H1N1) viruses were tested for oseltamivir resistance by a neuraminidase 
inhibition assay and/or detection of genetic sequence mutation, depending on the type of specimen 
tested.  Original clinical samples were examined for a single known mutation in the virus that 
confers oseltamivir resistance in currently circulating seasonal influenza A (H1N1) viruses, while 
influenza virus isolates were tested using a neuraminidase inhibition assay that determines the 
presence or absence of neuraminidase inhibitor resistance, followed by neuraminidase gene 
sequence analysis of resistant viruses.   
 
The majority of 2009 influenza A (H1N1) viruses are susceptible to the neuraminidase inhibitor 
antiviral medication oseltamivir; however, rare sporadic cases of oseltamivir resistant 2009 
influenza A (H1N1) viruses have been detected worldwide.  A total of 64 cases of oseltamivir 
resistant 2009 influenza A (H1N1) viruses have been identified in the United States since April 
2009. No new cases have been identified since last week.  Fifty-five of these specimens were 
collected after September 1, 2009.  The proportion of oseltamivir-resistant 2009 H1N1 viruses does 
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not represent the prevalence of oseltamivir-resistant 2009 H1N1 in the United States.  Most cases 
were tested because drug resistance was suspected.  All tested viruses retained their sensitivity to 
the neuraminidase inhibitor zanamivir.  Of the 64 total cases identified since April 2009, 52 patients 
had documented exposure to oseltamivir through either treatment or chemoprophylaxis, three 
patients had no drug exposure but possible exposure to a person with oseltamivir resistant 2009 
H1N1, five patients are under investigation to determine exposure to oseltamivir, three patients had 
neither documented oseltamivir exposure nor exposure to a person with oseltamivir resistant 2009 
H1N1, and in one patient, exposure cannot be determined.  Occasional development of oseltamivir 
resistance during treatment or prophylaxis is not unexpected.  Enhanced surveillance, an increased 
availability of testing performed at CDC, and an increasing number of public health and other 
clinical laboratories performing antiviral resistance testing increase the number of cases of 
oseltamivir resistant 2009 influenza A (H1N1) viruses detected.  All cases are investigated to assess 
the spread of resistant strains in the community.     
 
To prevent the spread of antiviral resistant virus strains, CDC reminds clinicians and the public of 
the need to continue hand and cough hygiene measures for the duration of any symptoms of 
influenza, even while taking antiviral medications 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5832a3.htm).  
 
Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 15, 7.6% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
at the epidemic threshold of 7.6% for week 15.  
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
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Influenza-Associated Pediatric Mortality:  No influenza-associated pediatric deaths were 
reported to CDC during week 15. 
 
Since August 30, 2009, CDC has received 272 reports of influenza-associated pediatric deaths that 
occurred during the current influenza season (48 deaths in children less than 2 years old, 30 deaths 
in children 2-4 years old, 102 deaths in children 5-11 years old, and 92 deaths in children 12-17 
years old).  Two hundred twenty-one (81%) of the 272 deaths were due to 2009 influenza A (H1N1) 
virus infections, 50 were associated with an influenza A virus for which the subtype is 
undetermined, and one was associated with an influenza B virus infection.  A total of 281 deaths in 
children associated with 2009 influenza A (H1N1) virus infection have been reported to CDC. 
 
Among the 272 deaths in children, 145 children had specimens collected for bacterial culture from 
normally sterile sites and 50 (34.5%) of the 145 were positive; Streptococcus pneumoniae was 
identified in 11 (22.0%) of the 50 children, and Staphylococcus aureus was identified in 15 (30.0%) 
of the 50 children.  Four S. aureus isolates were sensitive to methicillin, ten were methicillin 
resistant, and one did not have sensitivity testing performed.  Thirty-three (66.0%) of the 50 children 
with bacterial coinfections were five years of age or older, and 17 (34.0%) of the 50 children were 
12 years of age or older. 
 
Laboratory-Confirmed Influenza-Associated Pediatric Deaths by Date and 
Type/Subtype of Influenza. 
Date 2009 H1N1 Influenza 
Influenza A- 
Subtype 
Unknown 
Seasonal 
Influenza Total 
Number of Deaths REPORTED 
for Current Week – Week 15 
(Week ending April 17, 2010) 
0 0 0 0 
Number of Deaths OCCURRED 
since August 30, 2009 221 50 1 272 
Number of Deaths OCCURRED 
since April 26, 2009 281 53 3 337 
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Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations:  Laboratory-confirmed influenza-associated 
hospitalizations are monitored using a population-based surveillance network that includes the 10 
Emerging Infections Program (EIP) sites (CA, CO, CT, GA, MD, MN, NM, NY, OR and TN) and six 
new sites (IA, ID, MI, ND, OK and SD). 
During September 1, 2009 – April 17, 2010, the following preliminary laboratory-confirmed overall 
influenza associated hospitalization rates were reported by EIP and the new sites (rates include 
influenza A, influenza B, and 2009 influenza A (H1N1)): 
Rates [EIP (new sites)] for children aged 0-4 years and 5-17 years were 6.7 (10.7) and 2.5 (3.6) per 
10,000, respectively. Rates [EIP (new sites)] for adults aged 18-49 years, 50-64 years, and ≥ 65 
years were 2.4 (1.7), 3.2 (2.0) and 2.8 (1.8) per 10,000, respectively. 
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EIP Influenza Laboratory-Confirmed Cumulative Hospitalization Rates, 
2009-10 and Previous Three Seasons* 
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* The 2008-09 EIP rate ended as of April 14, 2009 due to the onset of the 2009 H1N1 season. 
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Outpatient Illness Surveillance: Nationwide during week 15, 1.1% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI).  This percentage is below the national baseline of 2.3%. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, October 1, 2006 – April 17, 2010 
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.3% to 2.3% during 
week 15.  All 10 regions reported ILI below region-specific baseline levels.  (Note: Use of the 
national baseline for regional ILI data or regional baselines for state-level data is not appropriate.) 
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists:  The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
both seasonal influenza and 2009 influenza A (H1N1) viruses and does not measure the severity of 
influenza activity. 
 
During week 15, the following influenza activity was reported: 
 No states reported widespread influenza activity. 
 No states reported regional influenza activity. 
 Local influenza activity was reported by and four states (Alabama, Georgia, Hawaii, and 
South Carolina). 
 Sporadic influenza activity was reported by the District of Columbia, Guam, Puerto Rico and 
31 states (Alaska, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana, Iowa, 
Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Nevada, 
New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, 
Tennessee, Texas, Virginia, Washington, Wisconsin, and Wyoming). 
 Fourteen states (Connecticut, Idaho, Maryland, Massachusetts, Montana, Nebraska, New 
Hampshire, North Dakota, Oregon, Rhode Island, South Dakota, Utah, Vermont, and West 
Virginia) reported no influenza activity. 
 The U.S. Virgin Islands and one state (Delaware) did not report. 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
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